$SanBio (4592.JP)$ Since the manufacturing method of Sunbio ...
Since the manufacturing method of Sunbio is different between an investigational drug and a mass-produced drug, an order has been received from the Ministry of Health, Labor, and Welfare to prove whether it is the same drug. However, even with the same manufacturing method, the effects of regenerative medicine drugs vary, and it is difficult to maintain homogeneity in quality, let alone a level where it is theoretically impossible if the manufacturing methods are different. When it comes to that, it is a study that assumes the worst pattern of re-testing from scratch using the current manufacturing method, the additional cost is about 30 billion, and the stop is cheap because of the calculation that takes 4 years.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
コツコツ投資家 : Will it triple if I buy it ('･ω･`)?
とるねこ OP コツコツ投資家 : The probability is really tough, but if homogeneity can be proven, drug prices are high, the doctor uses it, and the stroke goes well, it's 5 times higher! lol
とるねこ OP : Incidentally, traumatic brain injury cannot be profitable at all, because it is a drug that only accelerates cell division in young people whose brain cell division activity is significant. There is a misunderstanding, but it doesn't mean that the SB623 has playback ability. It only activates cell division. There is no qualitative resilience beyond natural healing.